Analytical Data
-
Gene name
LY6D
- Application
-
Alternative Names
Ly-6D; lymphocyte antigen 6 complex; locus D
-
Species
Human
-
Source
HEK293
-
Tag
C-mFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
CAA73189.1
-
Expression Region
L21-H97
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LY6D is a member of the Ly6/uPAR protein family, characterized by the presence of a glycine-rich domain and a potential role in cell signaling and immune regulation. Research has gained momentum due to its involvement in various biological processes including cell adhesion, proliferation, and differentiation, as well as its implications in cancer biology and immune responses. The expression of LY6D is noted in certain hematopoietic cells and has been associated with the promotion of T cell activation and the regulation of the immune microenvironment. Notably, studies have highlighted its potential as a marker for specific T cell populations, which positions LY6D as a candidate for therapeutic targeting in immunotherapy. Given the increasing interest in understanding immune checkpoints and the complexities of tumor-immune interactions, LY6D's role in modulating these processes offers insight into novel treatment strategies. Consequently, research involving the recombinant expression of LY6D protein aims to elucidate its functional mechanisms, interactions with other immune regulators, and its potential utility as a biomarker or therapeutic target in various diseases, particularly in oncology. This represents a significant step toward comprehensively understanding how LY6D can be leveraged in the development of immunotherapeutic interventions.
